6533b86efe1ef96bd12cb1cd
RESEARCH PRODUCT
Nutraceuticals and Cardiovascular Disease
Anca Pantea StoianPeter P. TothLuca Marco LuzzuAlexandros SachinidisDragana NikolicManfredi RizzoRoberta Chianettasubject
Cardiometabolic riskMediterranean dietbusiness.industryCardiovascular healthDiseasemedicine.diseaselaw.inventionNutraceuticalRandomized controlled triallawEnvironmental healthmedicinebusinessDyslipidemiaLipoprotein cholesteroldescription
Cardiovascular disease (CVD) remains the primary cause of mortality worldwide, taking an estimated 17.9 million lives each year. Among several cardiometabolic risk factors, dyslipidemia, and especially high low-density lipoprotein cholesterol (LDL-C) levels, are associated with the development and progression of atherosclerosis and its clinical sequelae. Recent studies have shown promising results for nutraceutical compounds on various CVD risk factors and complications. In addition to looking at individual nutrients or foods, dietary pattern have also emerged as a complementary approach to examine the relationship between the overall diet and the risk for CVD. The Mediterranean Diet (MedDiet) seems to provide the best dietary tools to improve cardiovascular health, although further large-scale randomized clinical trials are necessary to confirm this. In this chapter, we will discuss currently available data about the effects of nutraceuticals and some foods on different cardiometabolic risk factors and overall CVD risk. In addition, a brief discussion is provided on the role of MedDiet, including the international guidelines which support its use in prevention and/or treatment of subjects at CVD risk.
year | journal | country | edition | language |
---|---|---|---|---|
2021-01-01 |